Their passion motivated them to act when they saw the immense need around them. Motivated by the selfless desire to protect and help others, especially members of vulnerable populations, these employees jumped at the chance to join frontline medical efforts to combat COVID-19. Pfizer has created a Global COVID-19 Medical Service Program that enables medical colleagues to provide diagnostic, treatment, and public health support. Merck is collaborating with The Health Management Academy to identify facilities with the greatest need and triage qualifying volunteers to serve. Lilly is deploying its medical professionals to staff a free drive-through COVID-19 testing facility at its corporate headquarters in Indianapolis. The companies will maintain the base pay of those who volunteer and provide them with full benefits. Together, these major companies employ thousands of doctors, nurses, pharmacists, medical laboratory technicians, and other medical professionals whose services are in especially high demand during this crisis. Through Skills2Give, an ongoing BMS volunteer program with which over 3,000 employees are registered, colleagues in the US, UK, and Australia can select from virtual opportunities with thousands of nonprofit organizations.īiopharmaceutical companies Eli Lilly, Merck, and Pfizer have created programs empowering employees with medical or laboratory expertise to pause their current roles and to volunteer their skills to help local healthcare organizations. In addition, its employees across the world have volunteered their skills virtually. The expanded program offers access to BMS medicines for free, including some of the most widely prescribed products and those prescribed via telehealth services.īMS also supports its employees who are licensed healthcare professionals as they volunteer in local hospitals by providing them with full pay and benefits. On April 7 th, BMS expanded its existing programs to help eligible unemployed patients in the US who have lost their health insurance due to unemployment brought about by the COVID-19 pandemic. Recognizing that this is a challenging time for everyone and that patients are facing additional hardships, biopharmaceutical company Bristol Myers Squibb (BMS) expanded its patient support programs to offer critical relief. Gilead established a $20 million philanthropic fund, the Gilead CARES Grantee Fund, to support nonprofit organizations impacted by the COVID-19 crisis. Gilead continues to work closely with regulatory authorities to expand access programs for Remdesivir and has donated its existing supply, equaling 1.5 million individual doses for the treatment of patients with severe COVID-19 infection for clinical trials, compassionate use or expanded access programs, and following potential future regulatory authorizations. The company has set a goal of manufacturing more than 1 million treatment courses by the end of 2020 and several million in 2021. Gilead embarked on a resource- and time-intensive journey in January to accelerate manufacturing timelines to increase supply of Remdesivir. These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of 1,000 patients in the initial phase in countries with high prevalence of COVID-19. Gilead initiated two Phase 3 clinical studies to evaluate the safety and efficacy of Remdesivir in adults diagnosed with COVID-19. Gilead is harnessing decades of antiviral expertise, including more than 10 years of work on Remdesivir, an investigational medicine for COVID-19, to rapidly respond.
0 Comments
Leave a Reply. |